XNCR

Xencor, Inc. (XNCR) Q1 2025 10-Q Summary

Business Context and Reporting Period

This report covers the quarterly period ended March 31, 2025. Xencor, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics for cancer and autoimmune diseases. The company operates as a single reportable segment and relies on collaboration revenues, milestone payments, and royalties, as it has no internally developed products approved for commercial sale.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Revenue increased by $16.7 million (105%) year-over-year. This was driven by a $14.0 million increase in milestone revenue (primarily a $12.5 million regulatory milestone from Incyte for tafasitamab) and a $2.7 million increase in royalty revenue (driven by Alexion's Ultomiris).
• Reduced Net Loss: Net loss improved by $25.0 million compared to Q1 2024. The improvement was significantly aided by a reduction in asset impairment charges, which dropped from $20.7 million in Q1 2024 to $4.9 million in Q1 2025.
• Operating Expenses: Total operating expenses increased by $5.3 million to $75.9 million. Research and Development (R&D) expenses rose $1.7 million due to increased spending on programs XmAb819, XmAb657, and XmAb541. General and Administrative (G&A) expenses increased $3.6 million, primarily due to higher professional fees.
• Asset Impairment: The company recorded $4.9 million in asset impairment charges related to the decision to pause development of certain programs and prioritize resources toward other pipeline programs.

Guidance, Outlook, and Risks

• Liquidity: Management believes current financial resources are sufficient to fund operations through at least the next twelve months and potentially into 2028, assuming current operating plans hold.
• Pipeline Updates:
  • XmAb942 (IBD): Phase 1 results showed a half-life >71 days; Phase 2b study in ulcerative colitis expected to start in H2 2025.
  • Plamotamab (RA): Phase 1b/2a study planned for H1 2025.
  • XmAb657: First-in-human study planned for H2 2025.
• Internal Controls: The company disclosed that disclosure controls and procedures were not effective due to material weaknesses related to the accounting treatment of proceeds from the sale of future royalties and the evaluation of certain tax legislation. These weaknesses led to prior restatements. Remediation plans are underway.
• Legal Proceedings: Merus N.V. has sued Xencor alleging patent infringement regarding common light chain antibodies. Xencor has filed a motion to dismiss and an inter partes review seeking to invalidate the asserted patents.

Investor Verification Checklist

• Revenue Quality: Verify the cash collection status of the $12.5 million Incyte milestone (noted as paid in Q2 2025) and the $15.5 million Alexion royalty (non-cash, payable directly to OMERS).
• Internal Control Remediation: Monitor the progress of remediation for the material weaknesses in internal controls over financial reporting, specifically regarding non-routine transactions and tax legislation.
• Patent Litigation: Track the status of the Merus N.V. lawsuit and the outcome of the inter partes review filed with the USPTO.
• Program Prioritization: Assess the impact of pausing certain programs (resulting in $4.9M impairment) on the overall pipeline strategy and future R&D burn rate.
• Royalty Sale Liabilities: Review the effective interest rates (23.0% for Ultomiris, 17.5% for Monjuvi) and the prospective adjustments to the liability related to the sale of future royalties.